Showing results (511-520 of 831) with videos related to
Sort By:
Pageof 84
British Journal of Haematology|May 11, 2021
Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemiaHua-Jay J Cherng, Nadya Jammal, Shilpa Paul, et al.British Journal of Haematology|May 20, 2003
A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expressionFrancis J Giles, B Nebiyou Bekele, Susan O'Brien, et al.Cancer|December 24, 2003
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phaseThomas B Sneed, Hagop M Kantarjian, Moshe Talpaz, et al.Cancer|October 14, 2004
Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemiaHagop Kantarjian, Deborah Thomas, Susan O'Brien, et al.Blood|April 27, 2013
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalitiesPreetesh Jain, Hagop Kantarjian, Aziz Nazha, et al.Cancer|July 25, 2003
Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemiaHagop M Kantarjian, Susan O'Brien, Jorge Cortes, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2006
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignanciesKaren W L Yee, Zhihong Zeng, Marina Konopleva, et al.Clinical Lymphoma, Myeloma & Leukemia|February 4, 2016
Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML)Naveen Pemmaraju, Hagop Kantarjian, Farhad Ravandi, et al.Blood|May 3, 2002
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phaseHagop M Kantarjian, Jorge Cortes, Susan O'Brien, et al.Journal of the National Comprehensive Cancer Network : JNCCN|February 22, 2011
NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemiaSusan O'Brien, Ellin Berman, Joseph O Moore, et al.Pageof 84